by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
22/8/2021
June 2021 Review of news from the most innovative therapeutic areas and the business development transactions
SOTIO
Market
Multiple companies announced updated results during ASCO meeting
The ASCO annual meeting took place virtually beginning of June, where multiple companies presented their updated results of ongoing trials.
This led to share price changes and therefore to NBI increased beginning of June by 6% and remains now consistent.
Antibody-Drug Conjugates
ADC Therapeutics presented updated clinical data on its Zynlonta and Cami
Remegen Ltd.’s HER2-targeted disitamab vedotin became the first domestic ADC to win marketing approval in China, just three months after the company scored its first NDA approval in China for its lupus drug Tai’ai (telitacicept).
Interleukin-15 and Interleukin-2
Alkermes announced durable and deepening responses of its nemvaleukin in Phase 1/2
Alkermes announced new data from its ARTISTRY clinical development program for nemvaleukin alfa, the investigational engineered IL-2 variant immunotherapy. The data are being presented at ASCO.
Cell Therapies
China granted first CAR T approval to Fosun-Kite’s Yescarta
China’s drug regulator granted a first CAR T therapy approval to Fosun Kite Biotechnology’s FKC-876. Marketed as Yescarta (axicabtagene ciloleucel) in the US and EU, the approval by the National Medical Production Administration for the CD19-directed CAR T therapy came 3.5 years after the FDA nod.
Other Innovative Treatment Areas
Daiichi Sankyo wins approval in Japan for first-ever oncolytic virus therapy treating malignant glioma
Daiichi Sankyo has received conditional approval from Japan’s Ministry of Health, Labour and Welfare for its oncolytic virus Delytact (teserpaturev/G-47delta) to treat malignant glioma.
The approval marks the first-ever oncolytic virus therapy option to patients with glioblastoma and other malignant gliomas that are not controlled with currently available treatments. The therapy is Daiichi Sankyo’s fourth cancer medicine approved in Japan over the past two years.
Oncology Transactions
BMS pays $650 million upfront for anti-FOLR1 ADC from Eisai, plus $2.5 billion in milestones
PARTNERING
In the latest example of ADC attracting high-value deals, BMS is adding anti-FOLR1 ADC MORAb-202 to its pipeline through a $650 million collaboration with Eisai. The new deal supports BMS’s early pipeline strategy focused on broad mechanistic diversity.
Sdílet na sociálních sítích